iOncologi
iOncologi, Inc.
iOncologi, Inc. (iOi) is an innovative biotechnology company dedicated to pioneering novel immunotherapies for the treatment of refractory cancers and infectious diseases. With a strong emphasis on addressing the unmet medical needs of cancer patients who do not respond to existing treatments, iOncologi is at the forefront of transforming cancer therapy through advanced scientific research and development.
Products & Team
IONC201 and IONC202
IONC201 and IONC202 are advanced immunomodulatory stem cell therapies specifically designed to circumvent resistance to PD-1 blockade. They work by enhancing anti-tumor immune responses, offering a promising solution for patients who exhibit resistance to traditional immunotherapy.
These therapies address the critical issue faced by a significant portion of cancer patients who do not respond to conventional immunotherapies, aiming to improve treatment outcomes and survival rates.
Patients suffering from refractory cancers often face significant challenges as they are not responding to immune checkpoint inhibitors, leading to a lack of effective treatment options and adverse impacts on quality of life.